SCHEMBL17327969

SCHEMBL17327969

CCOC(=O)COc1ccc(CNc2cc(C)ccc2O)cc1OC(C)=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 4/20 0.43
▸ ALDH1A1 P00352 3/20 0.43
▸ MAPT P10636 3/20 0.43
▸ KMT2A Q03164 3/20 0.43
▸ KDM4E B2RXH2 2/20 0.43
▸ ALOX15 P16050 2/20 0.43
▸ HSD17B10 Q99714 2/20 0.43
▸ TSHR P16473 1/20 0.43
▸ TDP1 Q9NUW8 1/20 0.43
▸ HTT P42858 2/20 0.42
▸ NLRP3 Q96P20 1/20 0.42
▸ ESR1 P03372 1/20 0.42
▸ INSR P06213 1/20 0.41
▸ IGF1R P08069 1/20 0.41
▸ KCNMA1 Q12791 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ HDAC1 Q13547 1/20 0.38
▸ POLB P06746 2/20 0.37
▸ MAPK1 P28482 2/20 0.37
▸ HPGD P15428 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16294378 0.84 INSR (0.43) GAAALDH1A1MAPTKMT2AKDM4E
SCHEMBL17312349 0.80 GAA (0.41) GAAALDH1A1MAPTKMT2AKDM4E
SCHEMBL2717444 0.73 ESR1 (0.54) GAAALDH1A1KMT2AKDM4EHSD17B10
SCHEMBL16294684 0.72 ALDH1A1 (0.65) GAAALDH1A1MAPTKMT2AKDM4E
SCHEMBL27886154 0.71 CYP1A2 (0.51) GAAALDH1A1MAPTKMT2AHSD17B10
SCHEMBL16295256 0.71 ALDH1A1 (0.58) ALDH1A1MAPTKDM4ETDP1SMN1; SMN2
SCHEMBL17327987 0.71 ALDH1A1 (0.54) GAAALDH1A1MAPTKMT2AKDM4E
SCHEMBL17327970 0.71 TSHR (0.65) GAAALDH1A1KMT2AKDM4ETSHR
SCHEMBL9369313 0.70 USP2 (0.57) GAAALDH1A1MAPTKDM4EHTT
SCHEMBL10873018 0.69 MAPT (0.53) GAAALDH1A1MAPTKMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9549988-B2 Pharmaceutical compounds targeted by MIF affinity-tethered moieties RJS Biologics (US) 2017-01-24 — — US disclosed
US-9549988-B2 Pharmaceutical compounds targeted by MIF affinity-tethered moieties RJS Biologics (US) 2017-01-24 — — US disclosed
US-20150352217-A1 Pharmaceutical Compounds Targeted by MIF Affinity-Tethered Moieties RJS BIOLOGICS LLC 2015-12-10 — — US disclosed
US-20150352217-A1 Pharmaceutical Compounds Targeted by MIF Affinity-Tethered Moieties RJS BIOLOGICS LLC 2015-12-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150352217-A1 Pharmaceutical Compounds Targeted by MIF Affinity-Tethered Moieties MIF, HMGB2, HMGB1 GAA 1058/4885ALDH1A1 2238/4885MAPT 2168/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback